

Clinical Policy: Ultrasound in Pregnancy

Reference Number: LA.CP.MP.38 Date of last revision: <u>52</u>/23 Revision Log Coding Implications

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

This policy outlines the medical necessity criteria for ultrasound use in pregnancy. Ultrasound is the most common fetal imaging tool used today. Ultrasound is accurate at determining gestational age, fetal number, viability, and placental location; and is necessary for many diagnostic purposes in obstetrics. The determination of the time and type of ultrasound should allow for a specific clinical question(s) to be answered. Ultrasound exams should be conducted only when indicated and must be appropriately documented.

Policy/Criteria

It is the policy of Louisiana Healthcare Connections that a minimum of three obstetric ultrasounds during pregnancy are not subject to prior authorization requirements or prepayment medical review. When an obstetric ultrasound is performed for an individual with multiple gestations, leading to more than one procedure code being submitted, this shall only be counted as one obstetric ultrasound. Obstetric ultrasounds performed in inpatient hospital, emergency department, and labor and delivery triage settings are excluded from this count. For maternal fetal medicine specialists, there shall be no prior authorization or medical review required for reimbursement of obstetric ultrasounds In all cases, obstetric ultrasounds must be medically necessary to be eligible for reimbursement

I. One standard *first trimester ultrasound* (76801) is allowed per pregnancy.

Subsequent standard first trimester ultrasounds are considered not **medically necessary** as a limited or follow-up ultrasound assessment (76815 or 76816) should be sufficient to provide a re-examination of suspected concerns.

II. One standard *second or third trimester ultrasound* (76805) is allowed per pregnancy.

Subsequent standard second or third trimester ultrasounds are considered **not medically necessary** as a limited or follow-up ultrasound assessment (76815 or 76816) should be sufficient to provide a re-examination of suspected concerns.

III. One *detailed anatomic ultrasound* (76811) is allowed per pregnancy when performed to evaluate for suspected anomaly based on history, laboratory abnormalities, or clinical evaluation; or when there are suspicious results from a limited or standard ultrasound. Further indications include the possibility of fetal growth restriction and multifetal gestation. This ultrasound must be billed with an appropriate high risk diagnosis code from Table 4 below. Reimbursement for CPT codes 76811 and 76812 is restricted to maternal fetal medicine specialists. For maternal fetal medicine specialists, there shall be no prior authorization or prepayment medical review required for reimbursement of obstetric



ultrasounds. In addition, in all cases, obstetric ultrasounds must be medically necessary to be eligible for reimbursement.

A second detailed anatomic ultrasound is considered **medically necessary** if a new maternal fetal medicine specialist group is taking over care, a second opinion is required, or the patient has been transferred to a tertiary care center in anticipation of delivery of an anomalous fetus requiring specialized neonatal care.

Further <u>detailed</u> anatomic ultrasounds are considered **not medically necessary** as there is inadequate evidence of the clinical utility of multiple detailed fetal anatomic examinations.

- **IV.** *IV. Transvaginal ultrasounds (TVU)* are considered **medically necessary** when conducted in the first trimester for the same indications as a standard first trimester ultrasound, and later in pregnancy to assess cervical length, location of the placenta in women with placenta previa, or after an inconclusive transabdominal ultrasound. Cervical length screening is conducted for women with a history of preterm labor or to monitor a shortened cervix based on Table 1 below. Up to 13 transvaginal ultrasounds are allowed per pregnancy.
- in pregnancy to assess cervical length, location of the placenta in women with placenta previa, or after an inconclusive transabdominal ultrasound. Cervical length screening is conducted for women with a history of preterm labor or to monitor a shortened cervix based on Table 1 below.

Table 1: Berghella approach to TVU measurement of cervical length for screening singleton gestations

Past pregnancy history	TVU cervical length screening	Frequency	Maximum # of TVU
Prior preterm birth 14 to 27 weeks	Start at 14 weeks and end at 24 weeks	Every <u>two</u> ² weeks as long as cervix is at least 30 mm*	11
Prior preterm birth 28 to 36 weeks	Start at 16 weeks and end at 24 weeks	Every <u>two</u> ² weeks as long as cervix is at least 30 mm*	9
No prior preterm birth	One exam between 18 and 24 weeks	Once	1

* Increase frequency to weekly in women with TVU cervical length of 26 to 29 mm. through 24 weeks. If <25 mm before 24 weeks, consider cerclage.

- **V** *Fetal biophysical profiles* are covered and considered medically necessary when at least two of the following are met:
 - Gestation period is at least 28 weeks;
 - Pregnancy must be high risk, as determined by the provider; or
 - Uteroplacental insufficiency is suspected in a normal pregnancy.



- **VI** *Fetal Non-Stress Tests* are covered and considered medically necessary when one of the following is met:
 - The pregnancy is post-date/post-maturity (after 41 weeks gestation);
 - The treating provider suspects potential fetal problems in an otherwise normal pregnancy; or
 - The pregnancy is high risk, including but not limited to diabetes mellitus, pre-eclampsia, eclampsia, multiple gestations, and previous intrauterine fetal death.

VII. <u>3D and</u> 4D ultrasounds are considered not medically necessary. Studies lack sufficient evidence that they alter management over two-dimensional ultrasound in a fashion that improves outcomes.

The following additional procedures are considered not medically necessary:

- Ultrasounds performed solely to determine the sex of the fetus or to provide parents with photographs of the fetus;
- Scans for growth evaluation performed less than <u>two</u>² weeks apart;
- Ultrasound to confirm pregnancy in the absence of other indications;
- A follow-up ultrasound in the first trimester in the absence of pain or bleeding.

Classifications of fetal ultrasounds include:

I. Standard First Trimester Ultrasound - 76801

A standard first trimester ultrasound is performed before 14 weeks and 0 days of gestation. It can be performed transabdominally, transvaginally, or transperineally. When performed transvaginally, CPT 76817 should be used. It includes an evaluation of the presence, size, location, and number of gestational sac(s); and an evaluation of the gestational sac(s).

Indications for a first trimester ultrasound include the include, but are not limited to the following:

- To confirm an intrauterine pregnancy
- To evaluate a suspected ectopic pregnancy
- To evaluate vaginal bleeding
- To evaluate pelvic pain
- To estimate gestational age
- To diagnose <u>orand</u> evaluate multiple gestations
- To confirm cardiac activity
- As adjunct to chorionic villus sampling, embryo transfer, or localization and removal of an intrauterine device
- To assess for certain fetal anomalies, such as an encephaly, in high risk patients
- To evaluate maternal pelvic or adnexal masses or uterine abnormalities
- To screen for fetal aneuploidy (nuchal translucency) when a part of aneuploidy screening
- To evaluate suspected hydatidiform mole

II. Standard Second or Third Trimester Ultrasound - 76805



A standard ultrasound in the second or third trimester involves an evaluation of fetal presentation and number, amniotic fluid volume, cardiac activity, placental position, fetal biometry, and an anatomic survey.

Indications for a standard second or third trimester ultrasound include <u>but are not limited</u> to, the <u>the</u> following:

- Screening for fetal anomalies
- Evaluation of fetal anatomy
- Estimation of gestational age
- Evaluation of fetal growth
- Evaluation of vaginal bleeding
- Evaluation of cervical insufficiency
- Evaluation of abdominal <u>orand</u> pelvic pain
- Determination of fetal presentation
- Evaluation of suspected multiple gestation
- Adjunct to amniocentesis or other procedure
- Evaluation of discrepancy between uterine size and clinical dates
- Evaluation of pelvic mass
- Examination of suspected hydatidiform mole
- Adjunct to cervical cerclage placement
- Evaluation of suspected ectopic pregnancy
- Evaluation of suspected fetal death
- Evaluation of suspected uterine abnormality
- Evaluation of fetal well-being
- Evaluation of suspected amniotic fluid abnormalities
- Evaluation of suspected placental abruption
- Adjunct to external cephalic version
- Evaluation of prelabor rupture of membranes or premature labor
- Evaluation for abnormal biochemical markers
- Follow-up evaluation of a fetal anomaly
- Follow-up evaluation of placental location for suspected placenta previa
- Evaluation with a history of previous congenital anomaly
- Evaluation of fetal condition in late registrants for prenatal care
- Assessment for findings that may increase the risk of aneuploidy

III. Detailed Anatomic Ultrasound - 76811

A detailed anatomic ultrasound is performed when there is an increased risk of an anomaly based on the history, laboratory abnormalities, or the results of the limited or standard ultrasound.

IV. Other Ultrasounds – 76817

A transvaginal ultrasound of a pregnant uterus can be performed in the first trimester of pregnancy and later in a pregnancy to evaluate cervical length and the position of the placenta relative to the internal cervical os. When this exam is done in the first trimester, the same indications for a standard first trimester ultrasound, 76801, apply.



Background

The Routine Antenatal Diagnostic Imaging with Ultrasound (RADIUS) trial showed that routine ultrasound screening of a low-risk population did not lead to improved perinatal outcomes. This was a practice based, multi-center randomized trial. There were no significant differences in birth weight or preterm delivery rates.¹¹

<u>Ultrasound is used most often in pregnancy for the estimation of gestational age.⁵ It has been</u> shown that the use of multiple biometric parameters can allow for accuracy to within three to four days in a mid-trimester study (14 to 22 weeks). Accurate dating of a pregnancy is crucial as many important decisions might be made based on this date, such as whether or not to resuscitate an infant delivered prematurely, when to give antenatal steroids, when to electively deliver a term infant, and when to induce for post-dates.⁹

<u>Pregnancy dating with a first trimester or mid-trimester ultrasound will reduce the number of</u> <u>misdated pregnancies and subsequent unnecessary inductions for post-dates pregnancies. Third</u> <u>trimester ultrasounds for pregnancy dating are much less dependable.</u>

Ultrasound is a helpful tool for the evaluation of fetal growth in at-risk pregnancies and the diagnosis of a small-for-gestational age baby (SGA). Those SGA babies with actual chronic hypoxemia and/or malnutrition can be termed growth restricted (FGR) if it is suspected that their growth has been less than optimal.

The American College of Obstetricians and Gynecologists (ACOG) does not yet recommend the use of three- or four-dimensional ultrasound as a replacement for any necessary two-dimensional study. ACOG states, "the technical advantages of three-dimensional ultrasonography include its ability to acquire and manipulate an infinite number of planes and to display ultrasound planes traditionally inaccessible by two-dimensional ultrasonography. Despite these technical advantages, proof of a clinical advantage of three-dimensional ultrasonography in prenatal diagnosis in general still is lacking."⁵

The Society of Maternal Fetal Medicine specifically addresses what is often considered a level II screening ultrasound or routine ultrasound, stating:

"CPT 76811 is not intended to be the routine scan performed for all pregnancies. Rather, it is intended for a known or suspected fetal anatomic or genetic abnormality (i.e., previous anomalous fetus, abnormal scan this pregnancy, etc.). Thus, the performance of CPT 76811 is expected to be rare outside of referral practices with special expertise in the identification of, and counseling about, fetal anomalies.

It is felt by all organizations involved in the codes development and description that only one medically indicated CPT 76811 per pregnancy, per practice is appropriate. Once this detailed fetal anatomical exam (76811) is done, a second one should not be performed unless there are extenuating circumstances with a new diagnosis. It is appropriate to use CPT 76811 when a patient is seen by another maternal-fetal medicine specialist practice, for example, for a second opinion on a fetal anomaly, or if the patient is referred to a



tertiary center in anticipation of delivering an anomalous fetus at a hospital with specialized neonatal capabilities.

Follow-up ultrasound for CPT 76811 should be CPT 76816 when doing a focused assessment of fetal size by measuring the BPD [biparietal diameter], abdominal circumference, femur length, or other appropriate measurements, OR a detailed re-examination of a specific organ or system known or suspected to be abnormal. CPT 76805 would be used for a fetal maternal evaluation of the number of fetuses, amniotic/chorionic sacs, survey of intracranial, spinal, and abdominal anatomy, evaluation of a 4-chamber heart view, assessment of the umbilical cord insertion site, assessment of amniotic fluid volume, and evaluation of maternal adnexa when visible when appropriate."⁴

The Routine Antenatal Diagnostic Imaging with Ultrasound (RADIUS) trial showed that routine U/S screening of a low risk population did not lead to improved perinatal outcomes. This was a practice based, multi-center randomized trial. There were no significant differences in birth weight or preterm delivery rates.

Ultrasound is used most often in pregnancy for the estimation of gestational age. It has been shown that the use of multiple biometric parameters can allow for accuracy to within 3-4 days in a mid-trimester study (14-22 weeks). Accurate dating of a pregnancy is crucial as many important decisions might be made based on this date — whether or not to resuscitate an infant delivered prematurely, when to give antenatal steroids, when to electively deliver a term infant, and when to induce for post-dates.

Pregnancy dating with a first trimester or mid-trimester ultrasound will reduce the number of misdated pregnancies and subsequent unnecessary inductions for post-dates pregnancies. Third trimester ultrasounds for pregnancy dating are much less dependable.

Ultrasound is a helpful tool for the evaluation of fetal growth in at-risk pregnancies and the diagnosis of a small for gestational age baby (SGA). Those SGA babies with actual chronic hypoxemia and/or malnutrition can be termed growth restricted (FGR) if it is suspected that their growth has been less than optimal.

ACOG does not yet recommend the use of three- or four-dimensional ultrasound as a replacement for any necessary two-dimensional study. ACOG states "the technical advantages of three-dimensional ultrasonography include its ability to acquire and manipulate an infinite number of planes and to display ultrasound planes traditionally inaccessible by two-dimensional ultrasonography. Despite these technical advantages, proof of a clinical advantage of three-dimensional ultrasonography in prenatal diagnosis in general still is lacking."

The Society of Maternal Fetal Medicine specifically addresses what is often considered a level II screening U/S or routine U/S, stating:

"CPT 76811 is not intended to be the routine scan performed for all pregnancies. Rather, it is intended for a known or suspected fetal anatomic or genetic abnormality (i.e., previous anomalous fetus, abnormal scan this pregnancy, etc.). Thus, the performance of



CPT 76811 is expected to be rare outside of referral practices with special expertise in the identification of, and counseling about, fetal anomalies.

It is felt by all organizations involved in the codes development and description that only one medically indicated CPT 76811 per pregnancy, per practice is appropriate. Once this detailed fetal anatomical exam (76811) is done, a second one should not be performed unless there are extenuating circumstances with a new diagnosis. It is appropriate to use CPT 76811 when a patient is seen by another maternal-fetal medicine specialist practice, for example, for a second opinion on a fetal anomaly, or if the patient is referred to a tertiary center in anticipation of delivering an anomalous fetus at a hospital with specialized neonatal capabilities.

Follow-up ultrasound for CPT 76811 should be CPT 76816 when doing a focused assessment of fetal size by measuring the BPD [biparietal diameter], abdominal circumference, femur length, or other appropriate measurements, OR a detailed re-examination of a specific organ or system known or suspected to be abnormal. CPT 76805 would be used for a fetal maternal evaluation of the number of fetuses, amniotic/chorionic sacs, survey of intracranial, spinal, and abdominal anatomy, evaluation of a 4-chamber heart view, assessment of the umbilical cord insertion site, assessment of amniotic fluid volume, and evaluation of maternal adnexa when visible when appropriate."

Coding Implications

This clinical policy references Current Procedural Terminology (CPT[®]). CPT[®] is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 20220, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only and may not support medical necessity. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT Codes	Description
76801	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (<14 weeks 0 day), transabdominal approach; single or first gestation
76802	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; each additional gestation (List separately in addition to code for primary procedure)
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (\geq 14 weeks 0 day), transabdominal approach; single or first gestation

Table 2: CPT[®] Codes Covered When Supported by Appropriate Diagnosis



СРТ	Description
Codes	
76810	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; each additional gestation (List separately in addition to code for primary procedure)
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation (restricted to maternal fetal medicine specialists)
76812	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; each additional gestation (restricted to maternal fetal medicine specialists)
76813	Ultrasound, pregnant uterus, real time with image documentation, first trimester fetal nuchal translucency measurement, transabdominal or transvaginal approach; single or first gestation
76814	Ultrasound, pregnant uterus, real time with image documentation, first trimester fetal nuchal translucency measurement, transabdominal or transvaginal approach; each additional gestation
76815	Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses
76816	Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal
76818	Fetal biophysical profile; with non-stress testing
76819	Fetal biophysical profile; without non-stress testing
76820	Doppler velocimetry, fetal; umbilical artery
76821	Doppler velocimetry, fetal; middle cerebral artery
76825	Echocardiography, fetal, cardiovascular system, real time with image documentation (2D), with or without M-mode recording;
76826	Echocardiography, fetal, cardiovascular system, real time with image documentation (2D), with or without M-mode recording; follow-up or repeat study
76827	Doppler echocardiography, fetal, pulsed wave and/or continuous wave with spectral display; complete
76828	Doppler echocardiography, fetal, pulsed wave and/or continuous wave with spectral display; follow-up or repeat study
76830	Ultrasound, transvaginal



Table 4: ICD-10 Diagnosis Codes that Support Medical Necessity for First Detailed Fetal Ultrasound (ICD-10 codes with an + indicate additional digits are needed)

ICD-10-CM Code	Description
B06.00 through	Rubella [German measles] Rubella [German measles]
<u>B06.9</u> B06.00 B06.9	
B50.0 through	<u>Malaria</u>
<u>B54</u> B50.0 B54	
<u>B97.6</u> B97.6	Parvovirus as the cause of diseases classified elsewhereParvovirus as
	the cause of diseases classified elsewhere
<u>E66.01</u> E66.01	Morbid (severe) obesity due to excess calories [severe obesity with a
	BMI of 35 or >]Morbid (severe) obesity due to excess calories
	[severe obesity with a BMI of 35 or >]
009.511 through	Supervision of elderly primigravidaSupervision of elderly
<u>009.519</u> 009.511	primigravida
009.519	
O09.521 through	Supervision of elderly multigravidaSupervision of elderly
<u>009.529</u> 009.521	multigravida
009.529	
O09.811 through	Supervision of pregnancy resulting from assisted reproductive
<u>009.819</u> 009.811	technologySupervision of pregnancy resulting from assisted
009.819	reproductive technology
O24.011 through	Diabetes mellitus in pregnancy Diabetes mellitus in pregnancy
024.019, 024.111	
through O24.119,	
O24.311 through	
<u>O24.319, O24.811</u>	
through O24.819,	
<u>O24.911 through</u>	
<u>024.919</u> 024.011	
O24.019, O24.111	
024.119, 024.311	
024.319, 024.811	
024.819, 024.911	
024.919	
<u>028.3</u> 028.3	Abnormal ultrasonic finding on antenatal screening of
	motherAbnormal ultrasonic finding on antenatal screening of mother
<u>028.5</u> 028.5	Abnormal chromosomal and genetic finding on antenatal screening
	of motherAbnormal chromosomal and genetic finding on antenatal
	screening of mother
O30.001 through	Twin pregnancy Twin pregnancy
<u>O30.099</u> O30.001	
O30.099	
O30.101 through	Triplet pregnancy
<u>O30.199</u> O30.101	
O30.199	



ICD-10-CM Code	Description
O30.201 through	Quadruplet pregnancyQuadruplet pregnancy
O30.299 O30.201	
030.299	
O30.801 through	Other specified multiple gestation Other specified multiple gestation
O30.899 O30.801	
030.899	
O31.10X0 through	Continuing pregnancy after spontaneous abortion / intrauterine death
031.23X9 031.10x+-	of one fetus or more Continuing pregnancy after spontaneous
031.23x+	abortion / intrauterine death of one fetus or more
O33.6XX0 through	Maternal care for disproportion due to hydrocephalic fetusMaternal
O33.6XX9 O33.6xx+	care for disproportion due to hydrocephalic fetus
O33.7XX0 through	Maternal care for disproportion due to other fetal
033.7XX9 033.7xx+	deformities Maternal care for disproportion due to other fetal
	deformities
O35.00X0 through	Maternal care for (suspected) central nervous system malformation
O35.00X9 O35.0xx+	or damage in fetus, unspecified Maternal care for (suspected) central
	nervous system malformation in fetus
O35.01X0 through	Maternal care for (suspected) central nervous system malformation
O35.01X9 O35.1xx+	or damage in fetus, agenesis of the corpus callosumMaternal care for
	(suspected) chromosomal abnormality in fetus
O35.02X0 through	Maternal care for (suspected) central nervous system malformation
O35.02X9	or damage in fetus, an encephaly
O35.03X0 through	Maternal care for (suspected) central nervous system malformation
<u>O35.03X9</u> O35.2xx+	or damage in fetus, choroid plexus cystsMaternal care for (suspected)
	hereditary disease in fetus
O35.04X0 through	Maternal care for (suspected) central nervous system malformation
<u>035.04X9</u> 035.3xx+	or damage in fetus, encephaloceleMaternal care for (suspected)
	damage to fetus from viral disease in mother
O35.05X0 through	Maternal care for (suspected) central nervous system malformation
<u>O35.05X9</u> O35.4xx+	or damage in fetus, holoprosencephalyMaternal care for (suspected)
	damage to fetus from alcohol
O35.06X0 through	Maternal care for (suspected) central nervous system malformation
<u>O35.06X9</u> O35.5xx+	or damage in fetus, hydrocephalyMaternal care for (suspected)
	damage to fetus by drugs
O35.07X0 through	Maternal care for (suspected) central nervous system malformation
<u>O35.07X9</u> O35.6xx+	or damage in fetus, microcephalyMaternal care for (suspected)
	damage to fetus by radiation
O35.08X0 through	Maternal care for (suspected) central nervous system malformation
<u>O35.08X9</u> O35.8xx+	or damage in fetus, spina bifidaMaternal care for other (suspected)
	fetal abnormality and damage
O35.09X0 through	Maternal care for (suspected) other central nervous system
<u>O35.09X9</u> O35.9xx+	malformation or damage in fetusMaternal care for (suspected) fetal
	abnormality and damage, unspecified



ICD-10-CM Code	Description
O35.10X0 through	Maternal care for (suspected) chromosomal abnormality in
O35.10X9 O36.011+	fetusMaternal care for rhesus isoimmunization
036.099+	
O35.11X0 through	Maternal care for (suspected) chromosomal abnormality in fetus,
<u>035.11X9</u> 036.111+-	Trisomy 13Maternal care for other isoimmunization
036.199+	
O35.12X0 through	Maternal care for (suspected) chromosomal abnormality in fetus,
<u>035.12X9036.511+-</u>	Trisomy 18Maternal care for other known or suspected poor fetal
036.599+	growth
O35.13X0 through	Maternal care for (suspected) chromosomal abnormality in fetus,
O35.13X9 O40.1xx+-	Trisomy 21 Polyhydramnios
	_ <u></u> _ = =
O35.14X0 through	Maternal care for (suspected) chromosomal abnormality in fetus,
O35.14X9 O41.00x+	Turner Syndrome Oligohydramnios
$\overline{041.03x+}$	
O35.15X0 through	Maternal care for (suspected) chromosomal abnormality in fetus, sex
O35.15X9 O69.81x+	chromosome abnormality Labor and delivery complicated by other
069.89x+	cord complications
O35.19X0 through	Maternal care for (suspected) chromosomal abnormality in fetus,
O35.19X9 O71.9	other chromosomal abnormality Obstetric trauma, unspecified
O35.AXX0 through	Maternal care for other (suspected) fetal abnormality and damage,
035.AXX9 076	fetal facial anomalies Abnormality in fetal heart rate and rhythm
	complicating labor and delivery
O35.BXX0 through	Maternal care for other (suspected) fetal abnormality and damage,
O35.BXX9 O98.311	fetal cardiac anomalies Other maternal infectious and parasitic
098.319, 098.411	diseases complicating pregnancy
098.419, 098.511	
098.519, 098.611	
098.619, 098.711	
098.719, 098.811	
098.819	
O35.CXX0 through	Maternal care for other (suspected) fetal abnormality and damage,
<u>035.CXX9</u> 099.310-	fetal pulmonary anomalies Alcohol use complicating pregnancy
099.313	
O35.DXX0 through	Maternal care for other (suspected) fetal abnormality and damage,
<u>035.DXX9</u> 099.320	fetal gastrointestinal anomaliesDrug use complicating pregnancy
099.323	
O35.EXX0 through	Maternal care for other (suspected) fetal abnormality and damage,
<u>O35.EXX9</u> O99.411	fetal genitourinary anomalies Diseases of the circulatory system
099.419	complicating pregnancy
O35.FXX0 through	Maternal care for other (suspected) fetal abnormality and damage,
<u>O35.FXX9Q04.8</u>	fetal musculoskeletal anomalies of trunkOther specified congenital
	malformations of brain [choroid plexus cyst]



ICD-10-CM Code	Description	
O35.GXX0 through	Maternal care for other (suspected) fetal abnormality and damage,	
O35.GXX9 Q30.1	fetal upper extremities anomalies Agenesis and underdevelopment of	
	nose [absent or hypoplastic nasal bone]	
O35.HXX0 through	Maternal care for other (suspected) fetal abnormality and damage,	
<u>O35.HXX9Q62.0</u>	fetal lower extremities anomalies Congenital hydronephrosis [fetal	
	pyelectasis]	
O35.2XX0 through	Maternal care for (suspected) hereditary disease in fetus	
035.2XX9 Q71.811	shortening of upper limb [humerus]	
Q71.819		
O35.3XX0 through	Maternal care for (suspected) damage to fetus from viral disease in	
035.3XX9 072.811	motherCongenital shortening of lower limb [femur]	
Q72.819		
O35.4XX0 through	Maternal care for (suspected) damage to fetus from alcoholOther	
O35.4XX9 Q92.0	trisomies and partial trisomies of the autosomes, not elsewhere	
092.9	classified [fetuses with soft sonographic markers of aneuploidy]	
O35.5XX0 through	Maternal care for (suspected) damage to fetus by drugs	
O35.5XX9 R93.5	findings on diagnostic imaging of other abdominal regions, including	
000000000	retroperitoneum	
O35.6XX0 through	Maternal care for (suspected) damage to fetus by radiation	
O35.6XX9 R93.811-	findings on diagnostic imaging of other specified body structures	
R93.89	intenings on eneglissice integring of outer specified body structures	
O35.8XX0 through	Maternal care for other (suspected) fetal abnormality and	
035.8XX9 Z68.35	damageBody mass index [BMI] 35.0 70 or greater, adult	
<u>Z68.45</u>	<u>damage</u> body mass mack [Dirit] 55.6 76 of greater, addit	
O35.9XX0 through	Maternal care for (suspected) fetal abnormality and damage,	
035.9XX9	unspecified	
O36.0110 through	Maternal care for rhesus isoimmunization	
<u>O36.0999</u>	Indefinal care for mesus isommunization	
<u>O36.1110 through</u>	Maternal care for other isoimmunization	
<u>036.1999</u>	Indefinal cure for other isommunization	
<u>O36.5110 through</u>	Maternal care for other known or suspected poor fetal growth	
036.5999	Indefinal care for other known of suspected poor four growin	
040.1XX0	Polyhydramnios	
through O40.9XX9		
O41.00X0 through	Oligohydramnios	
041.03X9		
O69.81X0 through	Labor and delivery complicated by other cord complications	
<u>069.89X9</u>	Eusor and derivery compreteded by other cord compretations	
071.9	Obstetric trauma, unspecified	
076	Abnormality in fetal heart rate and rhythm complicating labor and	
010	delivery	
<u>098.311 through</u>	Other maternal infectious and parasitic diseases complicating	
<u>098.311 through</u> 098.319, 098.411		
	pregnancy	
<u>through 098.419,</u>		
<u>O98.511 through</u>		



ICD-10-CM Code	Description
098.519, 098.611	
through O98.619,	
O98.711 through	
098.719, 098.811	
through 098.819	
<u>O99.310 through</u>	Alcohol use complicating pregnancy
<u>099.313</u>	
<u>O99.320 through</u>	Drug use complicating pregnancy
<u>099.323</u>	
<u>O99.411 through</u>	Diseases of the circulatory system complicating pregnancy
<u>099.419</u>	
<u>Q04.8</u>	Other specified congenital malformations of brain [choroid plexus
	<u>cyst]</u>
<u>Q30.1</u>	Agenesis and underdevelopment of nose [absent or hypoplastic nasal
	bone]
<u>Q62.0</u>	Congenital hydronephrosis [fetal pyelectasis]
Q71.811 through	Congenital shortening of upper limb [humerus]
<u>Q71.819</u>	
Q72.811 through	Congenital shortening of lower limb [femur]
<u>Q72.819</u>	
Q92.0 through Q92.9	Other trisomies and partial trisomies of the autosomes, not elsewhere
	classified [fetuses with soft sonographic markers of aneuploidy]
<u>R93.5</u>	Abnormal findings on diagnostic imaging of other abdominal
	regions, including retroperitoneum
<u>R93.811 through</u>	Abnormal findings on diagnostic imaging of other specified body
<u>R93.89</u>	structures
Z68.35 through	Body mass index [BMI] 35.0 – 70 or greater, adult
<u>Z68.45</u>	

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Converted corporate to local policy.	08/15/2020	
Section IV.Table 1, revised note * Increase frequency to weekly in women with TVU cervical length of 25 to 29 mm, to 26 to 29mm and changed "If < 25 mm before 24 weeks…" to < = 25mm; edited maximum # TVU to 11 for prior preterm birth at 14-27 weeks, and 9 for prior preterm birth at 28 to 36 weeks. Changed total number of allowed TVUS per pregnancy to 13. Removed "experimental" from section V. Changed "review date" in the header to "date of last revision" and "date" in the revision log header to "revision date." References reviewed and updated.	12/2/2021	3/26/22
References reviewed and updated. Changed Members to members/enrollees. Specialist review.	7/22	9/26/22
Revised to add criteria for MFM Specialists, Fetal biophysical profiles, and Non-Stress Tests.	2/23	4/3/23



Reviews, Revisions, and Approvals	Revision Date	Approval Date
Annual review. Minor rewording in Description, in Table 1 under	<u>5</u> 3/23	
Criteria IV., and in Criteria V. Verbiage added to indicate list is not		
all inclusive under Classifications of fetal ultrasounds Section I.		
and Section II. Background updated with no impact on criteria.		
Updated Table 4 Coding description. The following retired code		
ranges were removed: O35.0XX0 through O35.0XX9 and		
O35.1XX0 through O35.1XX9. The following code ranges were		
added: O35.00X0 through O35.00X9, O35.01X0 through		
O35.01X9, O35.02X0 through O35.02X9, O35.03X0 through		
O35.03X9, O35.04X0 through O35.04X9, O35.05X0 through		
O35.05X9, O35.06X0 through O35.06X9, O35.07X0 through		
O35.07X9, O35.08X0 through O35.08X9, O35.09X0 through		
O35.09X9, O35.10X0 through O35.10X9, O35.11X0 through		
O35.11X9, O35.12X0 through O35.12X9, O35.13X0 through		
O35.13X9, O35.14X0 through O35.14X9, O35.15X0 through		
O35.15X9, O35.19X0 through O35.19X9, O35.AXX0 through		
O35.AXX9 , O35.BXX0 through O35.BXX9, O35.CXX0		
through O35.CXX9, O35.DXX0 through O35.DXX9, O35.EXX0		
through O35.EXX9, O35.FXX0 through O35.FXX9, O35.GXX0		
through O35.GXX9, O35.HXX0 through O35.HXX9. References		
reviewed and updated.		

References

- 1. Alldred SK, Takwoingi Y, Guo B, et al. First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening. *Cochrane Database Syst Rev.* 2017;3(3):CD012599. Published 2017 Mar 15. doi:10.1002/14651858.CD012599
- 2. American Academy of Pediatrics and American College of Obstetricians and Gynecologists (ACOG). *Guidelines for Perinatal Care* – Eighth Edition. 2017. https://www.acog.org/-/media/project/acog/acogorg/clinical/files/ebook/guidelines-for-perinatal-care.pdf. Accessed February 24, 2023.
- 3. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. *Obstet Gynecol.* 2021;137(2):e16 to e28. doi: 10.1097/AOG.00000000004251
- <u>4. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins</u>
 <u>Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. Screening for Fetal</u>
 <u>Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. Obstet Gynecol.</u>
 <u>2020;136(4):e48 to e69. doi:10.1097/AOG.0000000000004084</u>
- 5. American College of Obstetricians and Gynecologists'—Committee on Practice Bulletins— Obstetrics and the American Institute of Ultrasound in Medicine. Ultrasound in Pregnancy. No. 175. Published December 2016. (reaffirmed 2022). Accessed February 2, 2023.
- 6. AIUM-ACR-ACOG-SMFM-SRU Practice Parameter for the Performance of Standard Diagnostic Obstetric Ultrasound Examinations. J Ultrasound Med. 2018;37(11):E13 to E24. doi:10.1002/jum.14831



- 7. Berghella V. Short cervix before 24 weeks: Screening and management in singleton pregnancies. UpToDate website. www.uptodate.com. Published January 09, 2023. Accessed February 20, 2023.
- 8. Bricker L, Medley N, Pratt JJ. Routine ultrasound in late pregnancy (after 24 weeks' gestation). *Cochrane Database Syst Rev.* 2015;2015(6):CD001451. Published 2015 Jun 29. doi:10.1002/14651858.CD001451.pub4
- 9. Caradeaux J, Eixarch E, Mazarico E, Basuki TR, Gratacos E, Figueras F. Longitudinal growth assessment for the prediction of adverse perinatal outcome in fetuses suspected to be small-for-gestational age. *Ultrasound Obstet Gynecol*. 2018;52(3):325 to 331. doi:10.1002/uog.18824
- 10. Caughey AB, Nicholson JM, and Washington AE. First- vs. second-trimester ultrasound: the effect on pregnancy dating and perinatal outcomes. *Am J Obstet Gynecol* 2008;198(6):703.e1 to 703.e6. doi:10.1016/j.ajog.2008.03.034
- 11. Ewigman BG, Crane JP, Frigoletto FD, LeFevre ML, Bain RP, McNellis D.N. Effect of prenatal ultrasound screening on perinatal outcome. RADIUS Study Group.*N Engl J Med.* 1993;329(12):821-827. doi:10.1056/NEJM19930916329120.
- 12. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. *N Engl J Med* 2005;353(19):2001 to 2011. doi:10.1056/NEJMoa043693
- 13. Wax J, Minkoff H, Johnson A, et al. Consensus report on the detailed fetal anatomic ultrasound examination: indications, components, and qualifications. *J Ultrasound Med.* 2014;33(2):189 to 95. doi: 10.7863/ultra.33.2.189
- 14. Whitworth M, Bricker L, Mullan C. Ultrasound for fetal assessment in early pregnancy. <u>Cochrane Database Syst Rev. 2015;2015(7):CD007058. Published 2015 Jul 14. doi:</u> 10.1002/14651858.CD007058.pub3
- <u>15. Zhang J, Merialdi M, Platt LD, Kramer MS. Defining normal and abnormal fetal growth:</u> promises and challenges. Am *J Obstet Gynecol*. 2010;202(6):522 to 528. doi:10.1016/j.ajog.2009.10.889
- <u>16. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins</u> <u>Obstetrics. Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin,</u> <u>Number 234. Obstet Gynecol.</u> 2021;138(2):e65 to e90. doi:10.1097/AOG.00000000004479
- 1. Alldred SK, Takwoingi Y, Guo B, et al. First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening. *Cochrane Database Syst Rev.* 2017; 3(3):CD012599. Published 2017 Mar 15. doi:10.1002/14651858.CD012599.
- American Academy of Pediatrics and American College of Obstetricians and Gynecologists (ACOG). Guidelines for perinatal care eighth edition. 2017. <u>https://www.acog.org/</u> Accessed 2/07/2022.
- 3. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. *Obstet Gynecol*. 2021 Feb 1;137(2):e16-e28. doi: 10.1097/AOG.00000000004251.
- 4. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. *Obstet Gynecol*. 2020;136(4):e48-e69. doi:10.1097/AOG.0000000000004084.
- Committee on Practice Bulletins Obstetrics and the American Institute of Ultrasound in Medicine. Practice Bulletin No. 175: v Published December 2016. (reaffirmed 2020). Accessed February 4, 2022.



- 6. AIUM ACR ACOG SMFM SRU Practice Parameter for the Performance of Standard Diagnostic Obstetric Ultrasound Examinations. *J Ultrasound Med.* 2018;37(11):E13-E24. doi:10.1002/jum.14831.
- 7. Berghella V. Short cervix before 24 weeks: Screening and management in singleton pregnancies. UpToDate website. <u>www.uptodate.com</u>. Published June 22, 2020. Accessed February 10, 2022.
- 8. Bricker L, Medley N, Pratt JJ. Routine ultrasound in late pregnancy (after 24 weeks' gestation). *Cochrane Database Syst Rev.* 2015;2015(6):CD001451. Published 2015 Jun 29. doi:10.1002/14651858.CD001451.pub4.
- 9. Caradeaux J, Eixarch E, Mazarico E, Basuki TR, Gratacos E, Figueras F.. Longitudinal growth assessment for the prediction of adverse perinatal outcome in fetuses suspected to be small-for-gestational age. *Ultrasound Obstet Gynecol.* 2018;52(3):325-331. doi:10.1002/uog.18824.
- 10. Caughey AB, Nicholson JM, and Washington AE. First-vs. second-trimester ultrasound: the effect on pregnancy dating and perinatal outcomes. *Am J Obstet Gynecol* 008;198(6):703.e1-703.e6. doi:10.1016/j.ajog.2008.03.034.
- 11. Chervenak FA, Skupski DW, Romero R, et al. How accurate is fetal biometry in the assessment of fetal age? *Am J Obstet Gynecol* 1998;178(4):678-687. doi:10.1016/s0002-9378(98)70477-6.
- 12. Ewigman BG, Crane JP, Frigoletto FD, LeFevre ML, Bain RP, McNellis D.N. Effect of prenatal ultrasound screening on perinatal outcome. RADIUS Study Group.N Engl J Med. 1993;329(12):821-827. doi:10.1056/NEJM19930916329120.
- 13. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. *N Engl J Med* 2005;353(19) :2001–2011. doi:10.1056/NEJMoa043693.
- 14. Wax J, Minkoff H, Johnson A, Coleman B, Levine D, Helfgott A, O'Keeffe D, Henningsen C, Benson C. Consensus report on the detailed fetal anatomic ultrasound examination: indications, components, and qualifications. *J Ultrasound Med*. 2014 Feb;33(2):189-95. doi: 10.7863/ultra.33.2.189.
- 15. Whitworth M, Bricker L, Mullan C. Ultrasound for fetal assessment in early pregnancy. *Cochrane Database Syst Rev.* 2015(7):CD007058. Published 2015 Jul 14. doi: 10.1002/14651858.CD007058.pub3.
- 16. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. *N Engl J Med.* 1999: 341(7):461-467. doi:10.1056/NEJM199908123410701
- 17. Zhang J, Merialdi M, Platt LD, Kramer MS. Defining normal and abnormal fetal growth: promises and challenges. Am *J Obstet Gynecol*. 2010;202(6):522-528. doi:10.1016/j.ajog.2009.10.889.
- 18. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins Obstetrics. Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234. Obstet Gynecol. 2021;138(2):e65 e90. doi:10.1097/AOG.00000000004479

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional



organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©20203 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained



herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.